Table 2.
GCA 0 (n = 818) | GCA 1 (n = 220) | GCA 2/3 (n = 64) | GCA 1 vs GCA 0 | GCA 2/3 vs GCA 0 | GCA ≥ 1 vs GCA0 | ||||
a/acOR (95% CI) | p Value | a/acOR (95% CI) | p Value | a/acOR (95% CI) | p Value | ||||
90-d mRS, median (IQR) | 2 (1–3) | 3 (1–5) | 3 (2–6) | 1.55 (1.15–2.10) | 0.005 | 1.95 (1.18–3.23) | 0.009 | 1.62 (1.22–2.16) | 0.001 |
90-d mRS 0–2, n/N (%) | 539/818 (66) | 100/220 (46) | 26/64 (41) | 0.64 (0.43–0.94) | 0.023 | 0.71 (0.37–1.38) | 0.311 | 0.65 (0.45–0.94) | 0.02 |
90-d mRS 6, n/N (%) | 80/818 (10) | 47/220 (21) | 18/64 (28) | 2.16 (1.28–3.64) | 0.004 | 1.95 (0.86–4.43) | 0.111 | 2.12 (1.28–3.5) | 0.003 |
Adjustments were made for age, sex, final infarct volume, total WMD-burden, the interaction between alteplase and nerinetide, NIHSS at baseline, stroke laterality, and presence of chronic infarctions.